SCHEMBL18071081

SCHEMBL18071081

Nc1ncc(CC[C@H](N)C(=O)O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.46
GRIA2 P42262 2/20 0.46
GRIA4 P48058 2/20 0.46
GRIK1 P39086 1/20 0.46
GRIA3 P42263 1/20 0.46
GRIK2 Q13002 1/20 0.46
GRIK3 Q13003 1/20 0.46
AOC3 Q16853 1/20 0.44
GRM2 Q14416 2/20 0.42
CYP3A4 P08684 1/20 0.41
SLC7A5 Q01650 1/20 0.41
GRM8 O00222 1/20 0.41
GRM4 Q14833 1/20 0.41
ARG1 P05089 1/20 0.40
GRM6 O15303 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13095827 0.85 SLC7A5 (0.54) GRIA1GRIA2GRIA4GRIK1GRIA3
SCHEMBL5289317 0.85 SLC7A5 (0.54) GRIA1GRIA2GRIA4GRIK1GRIA3
SCHEMBL59810 0.85 SLC7A5 (0.54) GRIA1GRIA2GRIA4GRIK1GRIA3
SCHEMBL8225079 0.78 GRIA1 (0.42) GRIA1GRIA2GRIA4GRIK1GRIA3
SCHEMBL849758 0.75 SLC7A5 (0.51) GRIA1GRIA2GRIA4GRIK1GRIA3
SCHEMBL23824708 0.75 AOC3 (0.49) AOC3CYP1A2CYP2C9
SCHEMBL1769379 0.73 CYP3A4 (0.71) CYP3A4SLC7A5ALDH1A1
SCHEMBL1769375 0.73 CYP3A4 (0.71) CYP3A4SLC7A5ALDH1A1
SCHEMBL8225111 0.73 AOC3 (0.50) AOC3CYP3A4ALDH1A1CYP1A2CYP2C19
SCHEMBL31688512 0.72 GRIK1 (0.44) GRIA1GRIA2GRIA4GRIK1GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2022-06-02 US disclosed
US-11130780-B2 Inhibitors of growth factor activation enzymes WASHINGTON UNIVERSITY (US) 2021-09-28 US disclosed
WO-2020264187-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS JANETKA JAMES (US) 2020-12-30 WO disclosed
US-20180066015-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2018-03-08 US disclosed
WO-2016144654-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2016-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130780-B2 Inhibitors of growth factor activation enzymes HDGF, MMP7, HGF GRIA1 3737/4885GRIA2 4188/4885GRIA4 4518/4885
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES HDGF, MMP7, HGF GRIA1 3737/4885GRIA2 4188/4885GRIA4 4518/4885
US-20180066015-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES HDGF, MMP7, HGF GRIA1 3737/4885GRIA2 4188/4885GRIA4 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.